CO5570677A2 - Quinolinilpirrolopirazoles - Google Patents
QuinolinilpirrolopirazolesInfo
- Publication number
- CO5570677A2 CO5570677A2 CO05048136A CO05048136A CO5570677A2 CO 5570677 A2 CO5570677 A2 CO 5570677A2 CO 05048136 A CO05048136 A CO 05048136A CO 05048136 A CO05048136 A CO 05048136A CO 5570677 A2 CO5570677 A2 CO 5570677A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutically acceptable
- compound according
- prodrug
- ester
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 150000002148 esters Chemical class 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- -1 6-methylpyridin-2-yl Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42889302P | 2002-11-22 | 2002-11-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5570677A2 true CO5570677A2 (es) | 2005-10-31 |
Family
ID=32393478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05048136A CO5570677A2 (es) | 2002-11-22 | 2005-05-18 | Quinolinilpirrolopirazoles |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7265225B2 (enExample) |
| EP (1) | EP1565471B1 (enExample) |
| JP (1) | JP4542906B2 (enExample) |
| KR (1) | KR101057282B1 (enExample) |
| CN (1) | CN100345852C (enExample) |
| AT (1) | ATE341550T1 (enExample) |
| AU (1) | AU2003291643B2 (enExample) |
| BR (1) | BR0315337A (enExample) |
| CA (1) | CA2501322C (enExample) |
| CO (1) | CO5570677A2 (enExample) |
| CR (1) | CR7830A (enExample) |
| CY (1) | CY1106283T1 (enExample) |
| DE (1) | DE60308893T2 (enExample) |
| DK (1) | DK1565471T3 (enExample) |
| EA (1) | EA008387B1 (enExample) |
| EC (1) | ECSP055807A (enExample) |
| EG (1) | EG25822A (enExample) |
| ES (1) | ES2273046T3 (enExample) |
| HR (1) | HRP20050436B1 (enExample) |
| IL (1) | IL168190A (enExample) |
| MX (1) | MXPA05005432A (enExample) |
| NO (1) | NO331403B1 (enExample) |
| NZ (1) | NZ538942A (enExample) |
| PL (1) | PL227840B1 (enExample) |
| PT (1) | PT1565471E (enExample) |
| UA (1) | UA80571C2 (enExample) |
| WO (1) | WO2004048382A1 (enExample) |
| ZA (1) | ZA200503121B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| US7405299B2 (en) * | 2002-11-27 | 2008-07-29 | Eli Lilly And Company | Compounds as pharmaceutical agents |
| CA2616196C (en) * | 2005-07-22 | 2012-08-21 | Eli Lilly And Company | A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor |
| WO2007039151A1 (en) * | 2005-09-28 | 2007-04-12 | Universität Zürich | Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases |
| CN101553254A (zh) | 2006-10-03 | 2009-10-07 | 建新公司 | TGF-β拮抗物治疗具有罹患支气管肺发育不良风险的婴儿的用途 |
| EP2527345B1 (en) * | 2006-10-16 | 2015-12-16 | Thesan Pharmaceuticals, Inc. | Therapeutic pyrazolyl thienopyridines |
| CN103140474A (zh) | 2010-07-02 | 2013-06-05 | 吉里德科学公司 | 治疗aids的萘-2-基乙酸衍生物 |
| EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| MX2013012266A (es) | 2011-04-21 | 2013-11-22 | Gilead Sciences Inc | Compuestos de benzotiazol y su uso farmaceutico. |
| WO2013014262A1 (en) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating myhre syndrome |
| US9468612B2 (en) | 2011-10-26 | 2016-10-18 | Seattle Children's Hospital | Cysteamine in the treatment of fibrotic disease |
| US9782452B2 (en) | 2011-11-22 | 2017-10-10 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
| ES2571479T3 (es) | 2012-04-20 | 2016-05-25 | Gilead Sciences Inc | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
| CN105007939B (zh) | 2012-10-05 | 2018-10-19 | 卡德门企业有限公司 | 人抗vegfr-2/kdr抗体 |
| EP2917365B1 (en) | 2012-11-12 | 2020-03-11 | Institució Catalana de Recerca i Estudis Avançats | Methods and kits for the prognosis of colorectal cancer |
| JO3336B1 (ar) | 2014-10-07 | 2019-03-13 | Lilly Co Eli | مركبات أمينو بيريديلوكسي بيرازول |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| EP3277673B1 (en) | 2015-04-01 | 2022-05-04 | Rigel Pharmaceuticals, Inc. | Tgf-beta inhibitors |
| US10450318B2 (en) | 2015-12-15 | 2019-10-22 | Bristol-Myers Squibb Company | CXCR4 receptor antagonists |
| US10604528B2 (en) | 2016-07-07 | 2020-03-31 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Galunisertib crystalline form, preparation method thereof and use thereof |
| WO2018165979A1 (zh) * | 2017-03-17 | 2018-09-20 | 杭州领业医药科技有限公司 | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物 |
| WO2018170724A1 (zh) * | 2017-03-21 | 2018-09-27 | 杭州领业医药科技有限公司 | 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物 |
| WO2019042383A1 (zh) * | 2017-08-31 | 2019-03-07 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019105082A1 (zh) * | 2017-11-30 | 2019-06-06 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| WO2019137027A1 (zh) * | 2018-01-12 | 2019-07-18 | 苏州科睿思制药有限公司 | Galunisertib的晶型及其制备方法和用途 |
| EP3827010B1 (en) | 2018-07-23 | 2025-08-27 | Brise Pharmaceuticals Co., Ltd. | Bisphosphonate drug conjugates |
| SG11202103457PA (en) | 2018-12-27 | 2021-05-28 | Nexys Therapeutics Inc | (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer |
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| CN113557236B (zh) * | 2019-06-10 | 2022-05-10 | 中国科学院广州生物医药与健康研究院 | 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 |
| CN115052663B (zh) | 2020-01-08 | 2026-06-09 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
| JP7842690B2 (ja) | 2020-02-19 | 2026-04-08 | ナミ セラピューティクス， インコーポレイテッド | がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法 |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| GB202309553D0 (en) | 2023-06-24 | 2023-08-09 | Ucl Business Ltd | Compostions and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| ATE267830T1 (de) * | 1999-08-27 | 2004-06-15 | Abbott Lab | Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen |
| SI1397364T1 (sl) * | 2001-05-24 | 2007-12-31 | Lilly Co Eli | Novi pirolni derivati kot farmacevtske uäśinkovine |
| EP1567528A1 (en) | 2002-11-21 | 2005-08-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
-
2003
- 2003-10-11 UA UAA200504767A patent/UA80571C2/uk unknown
- 2003-11-10 EA EA200500859A patent/EA008387B1/ru not_active IP Right Cessation
- 2003-11-10 US US10/531,237 patent/US7265225B2/en not_active Expired - Fee Related
- 2003-11-10 DK DK03768531T patent/DK1565471T3/da active
- 2003-11-10 CN CNB2003801038400A patent/CN100345852C/zh not_active Expired - Fee Related
- 2003-11-10 MX MXPA05005432A patent/MXPA05005432A/es active IP Right Grant
- 2003-11-10 WO PCT/US2003/032747 patent/WO2004048382A1/en not_active Ceased
- 2003-11-10 NZ NZ538942A patent/NZ538942A/en not_active IP Right Cessation
- 2003-11-10 KR KR1020057009199A patent/KR101057282B1/ko not_active Expired - Fee Related
- 2003-11-10 JP JP2004555329A patent/JP4542906B2/ja not_active Expired - Fee Related
- 2003-11-10 AU AU2003291643A patent/AU2003291643B2/en not_active Ceased
- 2003-11-10 PT PT03768531T patent/PT1565471E/pt unknown
- 2003-11-10 PL PL376797A patent/PL227840B1/pl unknown
- 2003-11-10 ES ES03768531T patent/ES2273046T3/es not_active Expired - Lifetime
- 2003-11-10 EP EP03768531A patent/EP1565471B1/en not_active Expired - Lifetime
- 2003-11-10 HR HRP20050436AA patent/HRP20050436B1/hr not_active IP Right Cessation
- 2003-11-10 BR BR0315337-1A patent/BR0315337A/pt not_active Application Discontinuation
- 2003-11-10 AT AT03768531T patent/ATE341550T1/de active
- 2003-11-10 DE DE60308893T patent/DE60308893T2/de not_active Expired - Lifetime
- 2003-11-10 CA CA2501322A patent/CA2501322C/en not_active Expired - Fee Related
-
2005
- 2005-04-18 ZA ZA200503121A patent/ZA200503121B/en unknown
- 2005-04-21 IL IL168190A patent/IL168190A/en active IP Right Grant
- 2005-05-06 CR CR7830A patent/CR7830A/es unknown
- 2005-05-18 CO CO05048136A patent/CO5570677A2/es active IP Right Grant
- 2005-05-18 EG EGNA2005000237 patent/EG25822A/xx active
- 2005-05-19 EC EC2005005807A patent/ECSP055807A/es unknown
- 2005-06-21 NO NO20053045A patent/NO331403B1/no not_active IP Right Cessation
-
2006
- 2006-12-08 CY CY20061101769T patent/CY1106283T1/el unknown
-
2007
- 2007-07-25 US US11/782,659 patent/US7834029B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20045656L (no) | Oftalmologisk anvendelse av roflumilast for behandlingen av oyesykdommer | |
| ECSP045411A (es) | Derivados de quinolinona | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| TNSN05165A1 (fr) | Derives de pyrrolopyrimidine | |
| GEP20053673B (en) | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | |
| HN2004000232A (es) | " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden." | |
| CA2501322A1 (en) | Quinolinyl-pyrrolopyrazoles | |
| WO2007126964A3 (en) | Kinase inhibitors | |
| WO2005023759A3 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| BRPI0416989A (pt) | derivados aminopirazole como inibidores gsk-3 | |
| TW200626138A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| DE602004017194D1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| BRPI0409427A (pt) | composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo | |
| SV2002000036A (es) | Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma | |
| BRPI0413438A (pt) | derivados de pirimidilpirrol ativos como inibidores de cinase | |
| DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| PT1039900E (pt) | Agentes terapeuticos | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
| CY1107465T1 (el) | Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων | |
| DE60110592D1 (de) | Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer | |
| TW200502236A (en) | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | |
| WO2005055933A3 (en) | Treatment of psoriasis with rosiglitazone | |
| ATE298240T1 (de) | Getrennte dosis therapien mit gefässschädigender aktivität | |
| SE9900190D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused | ||
| FG | Application granted |